The merger of equals between Yamanouchi and Fujisawa completed effective April 1, 2005, forming Astellas Pharma Inc., then Japan's #2 pharmaceutical company, via a stock-for-stock share exchange with Yamanouchi as the legal surviving entity and no cash consideration. The combination united Fujisawa's Prograf transplant franchise with Yamanouchi's Harnal urology franchise on combined 2004 predecessor revenues of roughly $7.9 billion.